Rapport Therapeutics, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Rapport initiated Phase 3 FOCUS 1 and FOCUS 2 trials for RAP-219 in focal onset seizures in Q2 2026, with China NMPA approval granted for Phase 3 trials expected to enroll patients in Q4 2026. The company reported Q2 2026 net loss of $56.6M (vs. $26.7M YoY), R&D expenses of $51.4M (vs. $22.7M YoY), and ended with $436.1M in cash/short-term investments expected to fund operations into H2 2029. Bipolar mania Phase 2 topline results expected October 2026; RAP-219 half-life revised upward to 22 days from 14 days.
Why this rating
Phase 3 initiation is clinically meaningful and pipeline-advancing; modest 16% cash burn per quarter (Q2: $40.5M burn) is manageable. Material relative to $275.8M market cap but not transformational—success/failure outcomes remain binary and multi-year distant.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.